

Supplementary Table S1. Conditioning and induction treatment in post-transplant patients

	PTLD-HSCT n=23	Non-PTLD-HSCT n=25
Ablative conditioning (n) %		
Yes	9 (39.13%)	10 (40.00%)
Total Body Irradiation (TBI) and cyclophosphamide	3 (13.04%)	3 (12.00%)
TBI, fludarabine and thiotepa	1 (4.35%)	
TBI, fludarabine and cyclophosphamide	1 (4.35%)	1 (4.00%)
Fludarabine and thiotepa	1 (4.35%)	
Fludarabine, melphalan and thiotepa	3 (13.04%)	1 (4.00%)
Fludarabine and treosulfan		1 (4.00%)
TBI, melphalan and thiotepa		
Fludarabine, thiotepa and treosulfan		1 (4.00%)
Fludarabine, cyclophosphamide and busulfan		2 (8.00%)
Fludarabine and busulfan		1 (4.00%)
No	14 (60.87%)	15 (60.00%)
Fludarabine and busulfan	11 (47.83)	9 (36.00%)
Fludarabine and cyclophosphamide	3 (13.04%)	1 (4.00%)
Fludarabine		1 (4.00%)
Fludarabine, cyclophosphamide and TBI single fraction		3 (12.00%)
Fludarabine, cyclophosphamide and busulfan		1 (4.00%)
Consolidation method (n) %		
Chemotherapy	14 (60.90%)	20 (80.00%)
Cytarabine and anthracycline	6 (26.10%)	13 (52.00%)
Cytarabine, anthracycline and ATRA		1 (4.00%)
1 ABVD ¹ , BEACOPP ² , autologous transplantation (BEAM ³) and DHAP ⁴	1 (4.35%)	
R-CHOP ⁵ , autologous transplantation (BEAM) and R-DHAP ⁶	1 (4.35%)	
Cytarabine with anthracycline and autologous transplantation (busulfan, cyclophosphamide)	1 (4.35%)	
Multi-chemotherapy ALL protocol, with dasatinib and blinatumumab	1 (4.35%)	
R-CHOP, autologous transplantation (BEAM), ICE ⁷ and PI3K inhibitor	1 (4.35%)	
Chlorambucil and FCR ⁸	1 (4.35%)	
CHOP and DHAP	1 (4.35%)	
FC ⁹ , alemtuzumab and alvocidib	1 (4.35%)	
ABVD, DHAP, ICE, brentuximab		1 (4.00%)
VIP ¹⁰ , DHAP, autologous transplantation (BEAM); brentuximab, rituximab		1 (4.00%)
Multichemotherapy ALL protocol		2 (8.00%)
Bortezomib, thalidomide, dexamethasone, autologous transplantation (melphalan), carfilzomib, lenalidomide		1 (4.00%)
DHAP, CHOP, SMILE, alemtuzumab, nelarabine		1 (4.00%)
Immunosuppression	6 (26.10%)	1 (4.00%)
Alemtuzumab	2 (8.70%)	
Cyclosporine	2 (8.70%)	
Anti-thymocyte globulin (ATG)	1 (4.35%)	
Cyclosporine and ATG	1 (4.35%)	
Not defined		1 (4.00%)
Other	2 (8.70%)	

Hydroxyurea	1 (4.35%)	
Hydroxyurea and Ruxolutinib	1 (4.35%)	
No previous therapy	1 (4.35%)	4 (16.00%)

ABDV¹- doxorubicin hydrochloride (Adriamycin), bleomycin sulfate, vinblastine sulfate, and dacarbazine; BEACOP²- bleomycin sulfate, etoposide phosphate, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine sulfate (Oncovin), procarbazine hydrochloride, and prednisone; BEAM³- armustine, etoposide, cytarabine, and melphalan; (R-)DHAP^{4,6}- (rituximab), dexamethasone, high-dose cytarabine, cisplatin; (R)-CHOP⁵-(rituximab), cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone; ICE⁷-ifosfamide, carboplatin, and etoposide; FC(R)^{8,9}-fludarabine, cyclophosphamide, (rituximab); VIP¹⁰-etoposide, ifosfamide, and cisplatin; SMILE¹¹- dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide